Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Industries

    Local private firms to step up innovation

    By LIU ZHIHUA | China Daily | Updated: 2021-08-10 09:49
    Share
    Share - WeChat
    A researcher works at Clover Biopharmaceuticals' R&D center in Chengdu, Sichuan province. [Provided to China Daily]

    Clover received local government support to build a commercial manufacturing facility that completed construction in early 2020 in Huzhou, Zhejiang province.

    "Even though the company's drugs and vaccines were only in the preclinical stage then, their support allowed us to build a large facility that ended up being very important for our COVID vaccine program," Liang said.

    He also mentioned that the NMPA and its Center for Drug Evaluation have continued to expand their own capabilities, and the regulatory review timelines have been greatly shortened.

    The NMPA and CDE have also had a higher willingness to work together with biotech companies, and to have scientific and strategic discussions, he added.

    Shi Lichen, founder of Beijing Dingchen Consultancy, said Chinese pharmaceutical and biotech companies, among which many are non-State-owned, used to develop few self-developed original or innovative drugs. But things are changing mainly due to the improved regulatory environment, the stronger play of market mechanisms and booming venture capital/private equity investment.

    "China's medicine reforms in recent years are driving Chinese companies to focus more on new drug R&D and innovation to optimize product portfolios toward medium-to-high end returns, instead of simply profiting from the production and sales of low-quality generics," Shi said.

    Wei said most of the Chinese pharmaceutical enterprises focused on generics before regulatory reforms in 2015, but there are now a growing number of biotech companies developing innovative drugs.

    On the policy side, China joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, in 2017, and is actively implementing guidelines to encourage genuine indigenous innovations.

    In terms of industry practice, many Chinese pharmaceutical companies are establishing R&D centers and running clinical trials abroad. Cross-border deals have been active in the past few years, especially with a growing number of noticeable out-licensing deals, pointing to the future of "innovated in China", not just "made in China", he added.

    Industry insiders also said the booming VC/PE investment in China's pharmaceuticals sector has been further propelled by the pandemic and capital market reforms-such as the Science and Technology Innovation Board accepting listings from unprofitable companies and thus providing an exit mechanism for investors.

    According to global consultancy McKinsey & Co, there has been a strong rebound of healthcare VC/PE investment in 2020 after a decline in 2019. The total amount of VC/PE investment in the sector during the first half in 2020 had already exceeded that for the whole of 2019.

    Li Gang, partner of private investment bank CEC Capital, said accelerating reforms in China's capital market, including a registration-based system for IPOs and lower financial listing requirements, have provided investors clear exit strategies and thus have injected new momentum into healthcare investment.

    Liang said when he joined Clover in 2016, Chinese investors were still mainly looking at generics and biosimilars, while now there are many VC funds in China that want to support early-stage biotech companies, and some venture capital funds prefer to do Angel investing rounds, or even form companies from scratch.

    "The changing environment in the capital markets, with more funding for innovation, continues to support and foster continued growth of innovation in private Chinese pharmaceutical and biotech companies," Liang said.

    However, despite fast growth and increasing presence in the global industry arena, there is still a long way to go for China's non-State-owned pharmaceutical and biotech industry to become globally influential, experts said.

    Only 13 pharmaceutical and healthcare enterprises made the list of the top 500 Chinese private enterprises last year, which was released by the All-China Federation of Industry and Commerce.

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    日韩av无码中文字幕| 久久精品国产亚洲AV无码麻豆 | AV无码精品一区二区三区| 国产在线精品一区二区中文| 无码国产精成人午夜视频一区二区| 日韩乱码人妻无码中文字幕久久| 人妻中文字系列无码专区| 人妻丰满熟妇无码区免费| 无码AV动漫精品一区二区免费| 在线精品自拍无码| 国产av无码专区亚洲av桃花庵| 日韩精品无码免费专区午夜不卡| 色综合久久综合中文综合网| 97人妻无码一区二区精品免费| 亚洲中文字幕无码日韩| 久久亚洲精品无码VA大香大香| 丝袜熟女国偷自产中文字幕亚洲| 97久久精品无码一区二区天美| 99久久超碰中文字幕伊人| 中文字幕无码毛片免费看| 免费A级毛片无码无遮挡 | 中文字幕人妻色偷偷久久| 国产精品ⅴ无码大片在线看| 亚洲AV无码一区东京热| 亚洲Av无码精品色午夜| 久久精品无码一区二区WWW| 中文字幕一区二区免费| 最好看的电影2019中文字幕| 欧美日韩中文字幕在线看| 人妻无码人妻有码中文字幕| 日韩精品无码免费视频 | 亚洲最大av无码网址| 国产V亚洲V天堂无码久久久| 精品无码人妻一区二区免费蜜桃| 无码乱人伦一区二区亚洲一| 亚洲AV无码成人精品区蜜桃| 日本久久中文字幕| 免费无码午夜福利片69| 无码中文字幕日韩专区视频| 熟妇人妻中文字幕无码老熟妇| 国内精品人妻无码久久久影院 |